The management of acute myelogenous leukemia.
Although definite improvement in the treatment of acute myelogenous leukemia has taken place, the outlook  for patients remains grim. The current aggressive approach to treatment, entailing a program of chemotherapy which almost invariably produces bone marrow aplasia and considerable toxicity, has been the subject of some controversy. Selected aspects of management are discussed.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001803:Blood Transfusion; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D017053:Infection Control; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009181:Mycoses / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate